What is WynnVision?
Founded in 2016 by Dr. Kenneth J. Wynne, WynnVision operates at the intersection of material science and clinical safety. The company specializes in the development of advanced surface treatments designed to neutralize bacteria on contact and inhibit biofilm formation on medical devices. This technological focus addresses a critical pain point in modern healthcare: the prevalence of device-related infections that compromise patient outcomes and impose significant economic burdens on hospital systems. By integrating its antimicrobial solutions into existing medical hardware, WynnVision provides a robust defense against a broad spectrum of pathogens, effectively bridging the gap between laboratory innovation and practical clinical application.
How much funding has WynnVision raised?
WynnVision has raised a total of $88K across 1 funding round:
Debt
$88K
Debt (2021): $88K with participation from PPP
Key Investors in WynnVision
PPP
Public-Private Partnership
What's next for WynnVision?
With the recent infusion of capital, WynnVision is entering a pivotal phase of operational scaling. The company is expected to prioritize the expansion of its manufacturing capabilities and the deepening of its clinical validation pipeline. As the firm transitions from its current development stage toward broader market adoption, strategic focus will likely shift toward securing regulatory milestones and establishing partnerships with major medical device manufacturers. This growth trajectory suggests a concerted effort to standardize its infection-prevention technology as a benchmark for safety in surgical and long-term care environments, ultimately aiming to reduce the systemic costs associated with hospital-acquired complications.
See full WynnVision company page
